Related Experiment Video
Updated: Apr 23, 2026
11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
25.1K
GABA-mediated changes in inter-hemispheric beta frequency activity in early-stage Parkinson's disease
S D Hall1, E J Prokic2, C J McAllister2
1Aston Brain Centre, Aston University, Birmingham, West Midlands, UK; School of Psychology, Plymouth University, Devon, UK.
Neuroscience
|September 28, 2014
Summary
Low-dose zolpidem reduces beta power in Parkinson's disease (PD) motor cortex, improving symptoms. This GABAA receptor modulator rebalances brain activity between hemispheres, correlating with reduced motor impairment in PD patients.
Area of Science:
- Neuroscience
- Neurology
- Pharmacology
Background:
- Elevated beta power in motor networks is linked to Parkinson's disease (PD) symptoms.
- GABAA receptor modulation has shown potential for symptomatic improvement in PD.
Purpose of the Study:
- To investigate the effects of low-dose zolpidem on neuronal network activity in PD patients.
- To characterize changes in beta power and oscillations in the motor cortex following zolpidem administration.
Main Methods:
- Whole-head magnetoencephalography (MEG) was used to record brain activity in PD patients and controls.
- A beamforming 'virtual electrode' approach reconstructed oscillatory power in the primary motor cortex (M1).
- Recordings were taken before and after administration of low-dose zolpidem (0.05mg/kg).
Main Results:
- PD patients exhibited greater beta power in the contralateral M1 compared to the ipsilateral M1.
- Zolpidem significantly reduced contralateral M1 beta power and increased ipsilateral M1 beta power, balancing the hemispheric ratio.
- The changes in hemispheric beta power ratio strongly correlated with improvements on the Unified Parkinson's Disease Rating Scale (UPDRS).
Conclusions:
- Low-dose zolpidem effectively rebalances M1 network oscillations between hemispheres in PD patients.
- These neurophysiological changes induced by zolpidem are associated with symptomatic relief in Parkinson's disease.
- Zolpidem's modulation of GABAA receptors offers a potential therapeutic avenue for PD.
Keywords:
GABA(A) receptorsParkinson’s diseasebeta oscillationsmagnetoencephalographyprimary motor cortexMore Related Videos
10:46Acute In Vivo Electrophysiological Recordings of Local Field Potentials and Multi-unit Activity from the Hyperdirect Pathway in Anesthetized Rats
Published on: June 22, 2017
15.3K
07:03Evaluation of Hemisphere Lateralization with Bilateral Local Field Potential Recording in Secondary Motor Cortex of Mice
Published on: July 31, 2019
6.4K
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:24Parkinson Disease l: Introduction
12
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
12
01:24Parkinson Disease ll: Pathophysiology
16
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
16
01:11Alterations in Muscle Tone lll
22
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
22
01:37Neural Regulation
34.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
34.6K
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K